Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F16%3AE0105096" target="_blank" >RIV/00843989:_____/16:E0105096 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1007/s00066-015-0886-3" target="_blank" >http://dx.doi.org/10.1007/s00066-015-0886-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00066-015-0886-3" target="_blank" >10.1007/s00066-015-0886-3</a>

Result language

angličtina

Original language name

Hyperfractionated stereotactic reirradiation for recurrent head and neck cancer

Original language description

PURPOSE: The goal of this work was to evaluate the efficacy and toxicity of hyperfractionated stereotactic reirradiation (re-RT) as a treatment for inoperable, recurrent, or second primary head and neck squamous cell cancer (HNSCC) that is not suitable for systemic treatment. PATIENTS AND MATERIALS: Forty patients with recurrent or second primary HNSCC were included in this study. The patients had a median gross tumor volume of 76 ml (range 14-193 ml) and a previous radiotherapy dose greater than 60 Gy. Treatment was designed to cover 95?% of the planning target volume (PTV, defined as gross tumor volume [GTV] +?3 mm to account for microscopic spreading, with no additional set-up margin) with the prescribed dose (48 Gy in 16 fractions b.i.d.). Treatment was administered twice daily with a minimum 6 h gap. Uninvolved lymph nodes were not irradiated. RESULTS: Treatment was completed as planned for all patients (with median duration of 11 days, range 9-14 days). Acute toxicity was evaluated using the RTOG/EORTC scale. A 37?% incidence of grade 3 mucositis was observed, with recovery time of ??4 weeks for all of these patients. Acute skin toxicity was never observed to be higher than grade 2. Late toxicity was also evaluated according to the RTOG/EORTC scale. Mandible radionecrosis was seen in 4 cases (10?%); however, neither carotid blowout syndrome nor other grade 4 late toxicity occurred. One-year overall survival (OS) and local progression-free survival (L-PFS) were found to be 33 and 44?%, respectively. Performance status and GTV proved to be significant prognostic factors regarding local control and survival. CONCLUSION: Hyperfractionated stereotactic re-RT is a reasonable treatment option for patients with recurrent/second primary HNSCC who were previously exposed to high-dose irradiation and who are not candidates for systemic treatment or hypofractionation.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Strahlentherapie und Onkologie

ISSN

0179-7158

e-ISSN

—

Volume of the periodical

192

Issue of the periodical within the volume

n. 1

Country of publishing house

DE - GERMANY

Number of pages

7

Pages from-to

"p. 40-46"

UT code for WoS article

000371318900006

EID of the result in the Scopus database

—